Cancer patients were more likely to die from the BA.1 and BA.2 omicron variants of SARS-CoV-2 than from wild-type SARS-CoV-2, data suggest.
All articles by Andrea S. Blevins Primeau, PhD, MBA
Phase 3 data support brigatinib and alectinib as standard treatment options for patients with ALK-positive non-small cell lung cancer whose disease progressed on crizotinib, according to researchers.
Annual follow-up with 18FDG-PET/CT may improve survival, as compared to conventional follow-up, in patients with head and neck cancer.
Engaging in vigorous physical activity for 3 to 4 minutes per day is associated with a decrease in the risk of cancer among adults who typically don’t exercise, new research suggests.
Patients exposed to wildfire after curative-intent surgery for non-small cell lung cancer may have a higher risk of death than patients unexposed to wildfire.
Prior authorization requirements for oral cancer drugs on Medicare part D formularies have increased in recent years, research suggests.
Proton pump inhibitor use is associated with shorter survival among patients with non-small cell lung cancer treated with pembrolizumab monotherapy, a study suggests.
New research may explain why patients with CLL tend to respond poorly to COVID-19 vaccination.
Researchers have used a geriatric rating scale to show that childhood cancer survivors experience accelerated aging and have a higher risk of premature death than the general population.
Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.
The COVID-19 pandemic caused reductions in cancer diagnoses in 2020 that may pose challenges for interpreting long-term cancer trends.
The risk of in-hospital death from COVID-19 for patients with cancer differs by sex and cancer type, according to a new study.
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
COVID-19 vaccination may reduce the risk of COVID-19 sequelae in patients with cancer, according to researchers.
A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Adding chemotherapy to first-line treatment with gefitinib improves outcomes in patients who have EGFR-mutant non-small cell lung cancer with brain metastases, a phase 3 trial suggests.
Adding pembrolizumab to chemotherapy nearly doubles the 5-year overall survival rate in patients with advanced non-small cell lung cancer, phase 3 data suggest.
COVID-19 vaccines did not reduce the risk of severe COVID-19 among cancer patients who received radiation, CAR T-cell therapy, or HSCT.
Targeted therapies are underused in Medicaid patients with EGFR- or ALK-altered, metastatic non-small cell lung cancer, research suggests.
The combination of atezolizumab and bevacizumab appears effective as first-line treatment for patients with NSCLC and a high tumor mutation burden.
Performing liquid biopsy before tissue biopsy reveals more biomarkers in patients with non-small cell lung cancer, a study suggests.
Adding serplulimab to chemotherapy prolonged overall survival in patients with previously untreated, extensive-stage small cell lung cancer.
Pembrolizumab is a potential new treatment option for stage IB-IIIA non-small cell lung cancer after complete resection, according to researchers.
Many patients with advanced non-small cell lung cancer do not survive long enough to receive second-line therapy, a real-world study suggests.
Adjuvant osimertinib continues to demonstrate a disease-free survival benefit vs placebo in resected, stage IB-IIIA, EGFR-mutated non-small cell lung cancer.
The prevalence of metastatic cancers in the US has risen in recent years and will increase further by 2025, according to researchers.
A CT-based follow-up approach improved early detection of lung cancer recurrence and second primary lung cancers but did not improve survival.
Survivors of Hodgkin lymphoma may have a higher risk of developing lung cancer than former smokers, a study suggests.
Sintilimab, IBI305, and chemotherapy could be a new standard of care for patients with EGFR-mutant NSCLC that progressed on an EGFR TKI.